Skip to main content
European Heart Journal. Case Reports logoLink to European Heart Journal. Case Reports
. 2024 Aug 1;8(8):ytae392. doi: 10.1093/ehjcr/ytae392

An uncommon electrocardiogram presentation of bigeminy: ECG Challenge

Avinash Jeewooth 1, Atul Kaushik 2,2,, Aparna Jaswal 3
Editor: Parag Ravindra Gajendragadkar
PMCID: PMC11328535  PMID: 39156958

A 52-year-old male with a past history of hypertension, presented with pre-syncope for 15 days. His electrocardiogram is shown in Figure 1. His 2D echocardiogram (ECG), Cardiac-MRI, and coronary angiography were normal.

Figure 1.

Figure 1

12-lead echocardiogram (ECG) of the patient.

 

Question 1

The ECG shows an alternating pattern of narrow QRS complex with wider QRS complex. What is the likely diagnosis?

  1. Ventricular bigeminy.

  2. Atrial bigeminy with aberrancy.

  3. Ventricular tachycardia with capture beats.

  4. Ventricular tachycardia with fusion beats.

  5. SVT with aberrancy.

Answer: C.

Discussion and explanation

The heart rate in the ECG is around 120 b.p.m.

The wider QRS complex has a right bundle branch block pattern with a superior axis. The QRS duration of the complex is around 120 msec. The RS interval in the precordial leads is short. The broad complexes were not preceded by P waves. These findings favour a ventricular tachycardia (VT) originating close to the conduction system. The diagnosis is left posterior fascicular VT with alternating capture beats.

The narrower QRS complex is a capture beat. These beats are more commonly seen when the tachycardia rate is slow. The rate of the VT was unchanged.

Kindly refer to Supplementary material online, Image S1, for details.

Question 2

Which pharmacological drug is most effective against idiopathic fascicular VT?

  1. Lidocaine.

  2. Esmolol.

  3. Amiodarone.

  4. Verapamil.

  5. Adenosine.

Answer: D.

Discussion and explanation

Verapamil is the first-line treatment for acute termination of fascicular VT (ESC Guidelines Class IC recommendation).1 Fascicular VT is a macro-reentrant tachycardia which incorporates LPF as one limb of the circuit and abnormal Purkinje tissues as the other limb. These abnormal Purkinje tissues are calcium-dependent and hence the name ‘verapamil-sensitive idiopathic LV-VT’.

Question 3

What is the best chronic management option for this patient?

  1. Catheter ablation.

  2. Observation.

  3. Medical therapy.

  4. No follow-up required.

  5. Coronary angioplasty.

Answer: A.

Discussion and explanation

Catheter ablation is highly effective with a reported success rate of >85%.2

Kindly refer to Supplementary material online, Image S2, for details.

Supplementary Material

ytae392_Supplementary_Data

Contributor Information

Avinash Jeewooth, Department of Electrophysiology, Fortis Escorts Heart Institute (FEHI), Okhla, New Delhi 110025, India.

Atul Kaushik, Department of Cardiology, Fortis Escorts Heart Institute (FEHI), Okhla, New Delhi 110025, India.

Aparna Jaswal, Department of Electrophysiology, Fortis Escorts Heart Institute (FEHI), Okhla, New Delhi 110025, India.

Supplementary material

Supplementary material is available at European Heart Journal – Case Reports online.

Consent: Written consent was obtained from the patient for this manuscript.

Funding: No funding was required for this study.

Data availability

The data that support the findings of this study are available in the Supplementary material. Any other supporting data will be available from authors upon request.

References

  • 1. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126. [DOI] [PubMed] [Google Scholar]
  • 2. Schneider HE, Kriebel T, Jung K, Gravenhorst VD, Paul T. Catheter ablation of idiopathic left and right ventricular tachycardias in the pediatric population using noncontact mapping. Heart Rhythm 2010;7:731–739. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ytae392_Supplementary_Data

Data Availability Statement

The data that support the findings of this study are available in the Supplementary material. Any other supporting data will be available from authors upon request.


Articles from European Heart Journal. Case Reports are provided here courtesy of Oxford University Press

RESOURCES